Results of epigenetic modulation prior or after allogeneic stem cell transplantation (allo SCT) for myelodysplastic syndrome (MDS).
| Author . | n . | Indication . | Remission . | Outcome after allo SCT . |
|---|---|---|---|---|
| Abbreviations: CR, complete response; PR, partial response; TRM, treatment-related mortality; ORR, overall response rate; EFS, event-free survival; GVHD, graft-versus-host disease; cGVHD, chronic GVHD; AML, acute myeloid leukemia | ||||
| Lübbert33 | 10 | Decitabine prior allo SCT | 40% CR/10% PR | 33% relapsed/33% alive/33% TRM |
| De Padua34 | 12 | Decitabine prior allo SCT | 33% CR/50% PR | 75% alive/17% relapsed |
| McCarty35 | 25 | Azacytidine prior allo SCT | 52% ORR | Med EFS for azacytidine resp. pts: not reached for azactidine refractory patients: 7 months |
| Czibere52 | 6 | Relapse after allo SCT (azacytidine with DLI) | CR (n = 3) PR (n = 2) | No acute GVHD/cGvHD (n = 2); relapse (n = 3) |
| De Lima48 | 40 (AML+MDS) | Maintenance (azacytidine dose-finding study) | n.a | Mild toxicity, no increase of GvHD, relapse (n = 11) |
| Author . | n . | Indication . | Remission . | Outcome after allo SCT . |
|---|---|---|---|---|
| Abbreviations: CR, complete response; PR, partial response; TRM, treatment-related mortality; ORR, overall response rate; EFS, event-free survival; GVHD, graft-versus-host disease; cGVHD, chronic GVHD; AML, acute myeloid leukemia | ||||
| Lübbert33 | 10 | Decitabine prior allo SCT | 40% CR/10% PR | 33% relapsed/33% alive/33% TRM |
| De Padua34 | 12 | Decitabine prior allo SCT | 33% CR/50% PR | 75% alive/17% relapsed |
| McCarty35 | 25 | Azacytidine prior allo SCT | 52% ORR | Med EFS for azacytidine resp. pts: not reached for azactidine refractory patients: 7 months |
| Czibere52 | 6 | Relapse after allo SCT (azacytidine with DLI) | CR (n = 3) PR (n = 2) | No acute GVHD/cGvHD (n = 2); relapse (n = 3) |
| De Lima48 | 40 (AML+MDS) | Maintenance (azacytidine dose-finding study) | n.a | Mild toxicity, no increase of GvHD, relapse (n = 11) |